1. Home
  2. SHOO vs BEAM Comparison

SHOO vs BEAM Comparison

Compare SHOO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHOO
  • BEAM
  • Stock Information
  • Founded
  • SHOO 1990
  • BEAM 2017
  • Country
  • SHOO United States
  • BEAM United States
  • Employees
  • SHOO N/A
  • BEAM N/A
  • Industry
  • SHOO Shoe Manufacturing
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SHOO Consumer Discretionary
  • BEAM Health Care
  • Exchange
  • SHOO Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • SHOO 2.5B
  • BEAM 2.6B
  • IPO Year
  • SHOO 1993
  • BEAM 2020
  • Fundamental
  • Price
  • SHOO $34.92
  • BEAM $26.43
  • Analyst Decision
  • SHOO Buy
  • BEAM Strong Buy
  • Analyst Count
  • SHOO 8
  • BEAM 11
  • Target Price
  • SHOO $33.00
  • BEAM $49.40
  • AVG Volume (30 Days)
  • SHOO 1.2M
  • BEAM 2.6M
  • Earning Date
  • SHOO 11-05-2025
  • BEAM 11-05-2025
  • Dividend Yield
  • SHOO 2.41%
  • BEAM N/A
  • EPS Growth
  • SHOO N/A
  • BEAM N/A
  • EPS
  • SHOO 1.28
  • BEAM N/A
  • Revenue
  • SHOO $2,319,527,000.00
  • BEAM $60,272,000.00
  • Revenue This Year
  • SHOO $11.52
  • BEAM N/A
  • Revenue Next Year
  • SHOO $10.45
  • BEAM $19.01
  • P/E Ratio
  • SHOO $27.37
  • BEAM N/A
  • Revenue Growth
  • SHOO 7.97
  • BEAM N/A
  • 52 Week Low
  • SHOO $19.05
  • BEAM $13.53
  • 52 Week High
  • SHOO $46.99
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • SHOO 57.76
  • BEAM 52.40
  • Support Level
  • SHOO $34.18
  • BEAM $26.90
  • Resistance Level
  • SHOO $36.94
  • BEAM $28.71
  • Average True Range (ATR)
  • SHOO 1.26
  • BEAM 2.05
  • MACD
  • SHOO -0.14
  • BEAM -0.26
  • Stochastic Oscillator
  • SHOO 58.48
  • BEAM 36.20

About SHOO Steven Madden Ltd.

Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: